BIOMAT Database Logo BIOMAT Database Logo

Hepatitis C virus core antigen testing in liver and kidney transplant recipients. 2014

B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany.

HCV RNA levels correlate with the long-term outcome of hepatitis C in liver transplant recipients. Nucleic acid testing (NAT) is usually used to confirm HCV reinfection and to examine viral loads after liver transplantation. HCV core antigen (HCVcoreAg) testing could be an alternative to NAT with some potential advantages including very low intra- and interassay variabilities and lower costs. The performance of HCVcoreAg testing in organ transplant recipients is unknown. We prospectively studied 1011 sera for HCV RNA and HCVcoreAg in a routine real-world setting including 222 samples obtained from patients after liver or kidney transplantation. HCV RNA and HCVcoreAg test results showed a consistency of 98% with a very good correlation in transplanted patients (r > 0.85). The correlation between HCV RNA and HCVcoreAg was higher in sera with high viral loads and in samples from patients with low biochemical disease. Patients treated with tacrolimus showed a better correlation between both parameters than individuals receiving cyclosporine A. HCV RNA/HCVcoreAg ratios did not differ between transplanted and nontransplanted patients, and HCV RNA and HCVcoreAg kinetics were almost identical during the first days after liver transplantation. HCVcoreAg testing can be used to monitor HCV viral loads in patients after organ transplantation. However, the assay is not recommended to monitor antiviral therapies.

UI MeSH Term Description Entries
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Liver function tests in hepatitis C virus infected kidney transplant recipients.
April 1995, Transplantation proceedings,
B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients.
October 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Hepatitis C virus infection in kidney transplant recipients.
November 1993, Hepatology (Baltimore, Md.),
B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Hepatitis C virus infection in kidney transplant recipients.
June 1993, Transplantation proceedings,
B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Hepatitis C virus infection among kidney transplant recipients.
October 1991, Kidney international,
B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients.
September 1997, Transplantation,
B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Usefulness of liver biopsy in anti-hepatitis C virus antibody-positive and hepatitis C virus RNA-negative kidney transplant recipients.
July 2013, Transplantation,
B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients.
July 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation,
B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Systematic serological testing for hepatitis E virus in kidney transplant recipients.
May 2015, Journal of clinical microbiology,
B Heidrich, and S Pischke, and F A Helfritz, and I Mederacke, and J Kirschner, and J Schneider, and R Raupach, and E Jäckel, and H Barg-Hock, and F Lehner, and J Klempnauer, and T von Hahn, and M Cornberg, and M P Manns, and S Ciesek, and H Wedemeyer
Hepatitis C virus core antigen for screening organ donors and recipients.
June 2018, Diagnostic microbiology and infectious disease,
Copied contents to your clipboard!